07:00 , Jun 10, 2002 |  BC Week In Review  |  Company News

GPC Biotech, Pantherix deal

PanTherix acquired exclusive worldwide rights to GPC's antibacterial program in exchange for a note that converts into an undisclosed amount of PanTherix shares under certain conditions. The program includes bacterial targets and BioKey molecular probe...
07:00 , Jun 6, 2002 |  BC Extra  |  Company News

GPC, PanTherix antibacterials deal

PanTherix (Glasgow, U.K.) acquired exclusive worldwide rights to the antibacterials program of GPC Biotech (NMarkt:GPC) in exchange for a note that converts into an undisclosed amount of PanTHerix shares under certain conditions. The program includes...
08:00 , Feb 11, 2002 |  BC Week In Review  |  Company News

GPC Biotech, Karo Bio deal

KARO’s Karo Bio USA subsidiary (Durham, N.C.) and GPC completed their 2000 deal, under which KARO developed 10 Biokey molecular probe assays for selected GPC antibacterial targets (see BioCentury, June 19, 2000). KARO is eligible...
08:00 , Feb 6, 2002 |  BC Extra  |  Company News

Karo Bio, GPC complete assay deal

Karo Bio USA, a subsidiary of Karo Bio (SSE:KARO), and GPC Biotech (NMarkt:GPC) completed their 2000 deal under which KARO developed for GPC 10 Biokey molecular probe assays for selected antibacterial targets. KARO is eligible...
08:00 , Oct 30, 2000 |  BC Week In Review  |  Company News

Karo Bio, Aventis deal

KARO will provide AVE access to its BioKey high throughput screening assays for use with AVE's genomics-derived infectious disease targets. KARO said it could receive more than $32 million in the deal if two products...
07:00 , Oct 23, 2000 |  BC Extra  |  Company News

Karo in discovery deal with Aventis

Karo Bio (SSE:KARO) will provide AVE access to its BioKey high throughput screening assays, for use with AVE's genomics-derived infectious disease targets. KARO said it could receive more than $32 million in the deal if...
07:00 , Jun 19, 2000 |  BC Week In Review  |  Company News

GPC Biotech, Karo Bio deal

GPC and KARO's Karo Bio USA subsidiary (Durham, N.C.) will develop broad spectrum antibiotics based on genomics-derived targets. GPC will provide Karo Bio USA with up to 15 antibacterial targets, identified and validated through GPC's...
07:00 , Jun 15, 2000 |  BC Extra  |  Top Story

GPC and Karo genomics pact

GPC Biotech (NMarkt:GPC) and Karo Bio USA (Durham, N.C.), the U.S. subsidiary of Karo Bio (SSE:KARO), will develop broad-spectrum antibiotics based on genomics-derived targets. GPC will provide Karo Bio USA with up to 15 antibacterial...
08:00 , Jan 10, 2000 |  BC Week In Review  |  Company News

Novalon, Novartis deal

Novalon will non-exclusively provide to Novartis' Novartis Research Foundation BioKey screening assays for crop protection targets from Novartis's genomics program. Novalon will receive upfront, research, and commercial payments. Novalon Pharmaceutical Corp., Durham, N.C.   Novartis...
08:00 , Nov 9, 1998 |  BC Week In Review  |  Company News

Millennium, Novalon deal

MLNM was to announce today that it received access for one year to evaluate Novalon’s BioKey technology. The technology uses structured libraries of more than 20 billion biopolymers to identify surrogate ligands that bind specifically...